# Pharmaceutical industry licensing and expansion

> Developing situation record from CLSTR: https://clstr.news/situations/pharmaceutical-industry-licensing-and-expansion
> Updated: 2026-11-12T10:11:08.000Z. Sources: 7. Developments: 2.

The pharmaceutical sector has seen significant investment and licensing activity. AbbVie is expanding its research and development operations in Oxford, UK, by establishing a new 12,000 square foot facility as part of a broader £120 million commitment to the UK life sciences sector. Additionally, AbbVie has signed an exclusive global licensing agreement with Japan-based Nxera, valued at up to $1.37 billion, to develop a treatment for inflammatory bowel disease.

In a separate major transaction, Novartis has entered into a licensing and options agreement with China-based Abogen Biosciences. This deal is valued at up to $7.8 billion, including a $575 million upfront payment and milestone-based conditional payments. Through this agreement, Novartis secures worldwide exclusive rights to the mRNA-encoded T-cell engager ABO2203 and options for future programs on Abogen’s mRNA platform to treat B-cell mediated autoimmune diseases.

## Timeline

### 2026-11-12: Novartis to license mRNA therapies from Abogen in $7.8 billion deal

Novartis has signed a deal worth up to $7.8 billion with Abogen Biosciences to license mRNA-based therapies for autoimmune diseases.

5 sources. https://clstr.news/cluster/novartis-to-license-mrna-therapies-from-abogen-in-78-billion-deal

### 2026-11-06: AbbVie expands Oxford research facility and signs $1.37 billion drug deal

AbbVie is expanding its Oxford R&D facility as part of a £120 million UK investment and has signed a $1.37 billion licensing deal with Japan's Nxera for an inflammatory bowel disease treatment.

2 sources. https://clstr.news/cluster/abbvie-expands-oxford-research-facility-and-signs-137-billion-drug-deal

---
Cite as: Pharmaceutical industry licensing and expansion. CLSTR, https://clstr.news/situations/pharmaceutical-industry-licensing-and-expansion
